Combination therapy with interferon-γ and interleukin-2 for the treatment of metastatic melanoma

Journal of Immunotherapy

Volumn 19, Issue 1, 1996, Pages 50-58

  Kim, Christina J ^a   Taubenberger, Jeffery K ^c   Simonis, Toni B ^b   White, Donald E ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Interferon ; Interleukin 2; Melanoma

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALAISE; MALE; MELANOMA; METASTASIS; NAUSEA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VOMITING;

EID: 0029871645     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199601000-00006     Document Type: Article

References (47)

1. Rosenberg SA, Schwarz SL, Spiess, PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 1988;80:1393-7.
2. Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). J Immunol 1985;134:3124-9.
3. McAdam A, Pulaski B, Harkins S, Hutter E, Frelinger J, Lord E. Coexpression of IL-2 and gamma-IFN enhances tumor immunity. Ann NY Acad Sci 1993;690:349-51.
4. Kirkwood JM, Ernstoff MS. Interferons - clinical applications: cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:311-33.
5. Fleischmann WR, Fleischmann CM. Mechanisms of interferons' anti-tumor actions. In: Cooperhaven BS, ed. Interferon: principles and medical applications. Galveston, TX: University of Texas Medical Branch, 1992:299-309.
6. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
7. Scher RL, Koch WM, Richtsmeier WJ. Induction of the intercellular adhesion molecule (ICAM-1) on squamous cell carcinoma by interferon gamma. Arch Otolaryngol Head Neck Surg 1993;119:432-8.
8. Ramsey PS, Dean PA, Tasimowicz-Alpini A, Donohue JH, Nelson H. Interferon-gamma-induced intercellular adhesion molecule-1: expression on human tumor cells enhances bifunctional antibody-mediated lysis through a lymphocyte function-associated antigen-1 dependent mechanism. Cancer Res 1993;53:4652-7.
9. Greiner JW, Guadagni F, Goldstein D, et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992;10:735-46.
10. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
11. Le J, Prensky W, Yip YK, et al. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J Immunol 1983;131:2821-6.
12. Leibson HJ, Gefter M, Zlotnik A, Marrack P, Kappler JW. Role of gamma-interferon in antibody-producing responses. Nature 1984;309:799-801.
13. Natali PG, Nicotra MR, Bigotti A, et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Nail Acad Sci USA 1989;86:6719-23.
14. Marincola FM, Shamamian P, Simonis TB, et al. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother 1994;16:13-23.
15. Stotter H, Wiebke EA, Tomita S, et al. Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol 1989;142:1767-73.
16. Agah R, Malloy B, Sherrod A, Mazumder A. Successful therapy of natural killer-resistant pulmonary metastases by the synergism of gamma-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res 1988;48:2245-8.
17. Weber JS, Rosenberg SA. Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst 1990;82:755-61.
18. Redman BG, Flaherty L, Chou TH, et al. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. J Clin Oncol 1990;8: 1269-76.
19. Hu E, Watkins K, Groshen S, et al. Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies. Mol Biother 1990;2: 96-103.
20. Baars JW, Wagstaff J, Boven E, et al. Phase I study on the sequential administration of recombinant human interferon-gamma and recombinant human interleukin-2 in patients with metastatic solid tumors. J Natl Cancer Inst 1991;83: 1408-10.
21. Margolin KA, Doroshow JH, Akman SA, et al. Phase I trial of interleukin-2 plus gamma-interferon. J Immunother 1992; 11:50-5.
22. Farace F, Mathiot C, Brandely M, et al. Phase I trial with recombinant interleukin-2 (rlL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma. Clin Exp Immunol 1990;82:194-9.
23. Taylor CW, Chase EM, Whitehead RP, et al. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer. J Immunother 1992;11:176-83.
24. Viens P, Biaise D, Stoppa AM, et al. Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer. J Immunother 1992;11:218-24.
25. Vadhan-Raj S, al-Katib A, Bhalla R. et al. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 1986;4:137-46.
26. Escudier B, Farace F, Angevin E, et al. Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma. Eur J Cancer 1993;29A:724-8.
27. Maluish AE, Urba WJ, Longo DL, et al. The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 1988;6:434-45.
28. Thompson JA, Cox WW, Lindgren CG, et al. Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother 1987;25:47-53.
29. Sherwin SA, Foon KA, Abrams PG, et al. A preliminary phase I trial of partially purified interferon-gamma in patients with cancer. J Biol Response Mod 1984;3:599-607.
30. Marincola FM, Rosenberg SA. Biologic therapy with interleukin-2: clinical applications - melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1995:250-62.
31. Taubenberger JK, Cole DE, Raffeld M, Poplack DG, Jaffe ES, Medeiros LJ. Immunophenotypic analysis of acute lymphoblastic leukemia using routinely processed bone marrow specimens. Arch Pathol Lab Med 1991;115:338-42.
32. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990;19:390-9.
33. Marincola FM, Venzon D, White D, et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy [published erratum appears in Cancer Res 1993; 53(16):3846]. Cancer Res 1992; 52:6561-6.
34. Ferrone S, Marincola FM, Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16: 487-94.
35. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-84.
36. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with intereron alpha-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13:1110-22.
37. Smith JW, Urba WJ, Clark JW, et al. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. J Immunother 1991;10: 355-62.
38. Montaldo PG, Carbone R, Corrias MV, Ferraris PC, Ponzoni M. Synergistic differentiation-promoting activity of interferon gamma and tumor necrosis factor-alpha: role of receptor regulation on human neuroblasts. J Natl Cancer Inst 1994;86:1694-1701.
39. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas J Immunol 1989;142:3714-25.
40. Kirkwood JM, Ernstoff MS, Trautman T, et al. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol 1990;8:1070-82.
41. Osanto S, Jansen R, Naipal AM, Gratama JW, van Leeuwen A, Cleton FJ. In vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma. Int J Cancer 1989;43:1001-6.
42. Landmann R, Ludwig C, Wesp M, et al. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens. J Interferon Res 1992;12:103-11.
43. Ghosh AK, Cerny T, Wagstaff J, Thatcher N, Moore M. Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma. Eur J Cancer Clin Oncol 1989;25:1637-43.
44. Kowalzick L, Weyer U, Lange P, Breitbart EW. Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast intetferon-beta and recombinant interferon-gamma. Dermatologica 1990;181:298-303.
45. Ozzello L, Habif DV, De Rosa CM, Cantell K. Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Res 1992;52: 4571-81.
46. Gutterman JU, Rosenblum MG, Rios A, Fritsche HA, Quesada JR. Pharmacokinetic study of partially pure gamma-interferon in cancer patients. Cancer Res 1984;44:4164-71.
47. Yanase M, Tsukamoto T, Kumamoto Y, Kato K, Hashimoto Y. Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment. Cancer Immunol Immunother 1994;39:22-6.